- Home
- REBN vs MBRX Comparison
REBN vs MBRX Comparison
Compare REBN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | MBRX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.6M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | REBN | MBRX |
|---|---|---|
| Price | $1.48 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 46.1K | ★ 621.5K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,663,303.00 | N/A |
| Revenue This Year | $335.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.09 | N/A |
| 52 Week Low | $1.20 | $3.13 |
| 52 Week High | $8.30 | $91.25 |
Technical Indicators
Market Signals| Indicator | REBN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 45.43 |
| Support Level | $1.38 | $3.13 |
| Resistance Level | $1.55 | $4.24 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 29.94 | 7.76 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.